title: [Changes of Von Willebrand factor concentration during pregnancy].
abstract: The multimeric glycoprotein Von Willebrand factor (vWF), is produced by vascular endothelium and platelet. If some constitutionals deficiencies leading to hemorrhagic syndrome have been explored in the literature, increased production of vWF observed during cellular distress and pregnancy have not been explored in our milieu. The aim of this study was to determine vWF changes during pregnancy in a group of Cameroonian women and find out the possibility of using it as a marker of fetal distress. Serum was collected from 46 women in the second and third trimesters of pregnancy. The determination of vWF concentration was performed using the Asserachrom vWF reagent: Ag (Diagnostica Stago, France). The average concentrations of vWF in the second and third trimester samples were respectively 215.47 ± 9.38% (UI/dL) and 264.09 ± 11.58% (UI/dL). The difference between (i) concentrations of vWF during the second and third trimester of pregnancy was statistically significant (P-value<0.0001); (ii) concentrations of vWF according to mother's ages was not significant; (iii) concentrations of vWF in blood group O and B women was statistically significant (P-value<0.05). We observed a difference between vWF values in women whose babies had Apgar score 4 to 6 compared to those with Apgar score between 7 and 10. The different was not statistically significant probably due to low effective. In conclusion, vWF production during the pregnancy varies with gestational age and maternal blood group. It may increases during fetal distress.
authors.affiliation: Université de Douala, Faculté de médecine et des sciences pharmaceutiques, Cameroun, Hôpital général de Douala, Cameroun.
authors.forename: Symphorien
authors.initials: S
authors.lastname: Ewodo
authors.affiliation: Université de Douala, Faculté de médecine et des sciences pharmaceutiques, Cameroun, Hôpital général de Douala, Cameroun.
authors.forename: Charlotte Tchente
authors.initials: CT
authors.lastname: Nguefack
authors.affiliation: Université de Douala, Faculté de médecine et des sciences pharmaceutiques, Cameroun.
authors.forename: Dieudonné
authors.initials: D
authors.lastname: Adiogo
authors.affiliation: Université de Douala, Faculté de médecine et des sciences pharmaceutiques, Cameroun.
authors.forename: Ebolo Marcelle Rosie
authors.initials: EM
authors.lastname: Etong
authors.affiliation: Université de Douala, Faculté de médecine et des sciences pharmaceutiques, Cameroun, Hôpital général de Douala, Cameroun.
authors.forename: Gérard
authors.initials: G
authors.lastname: Beyiha
authors.affiliation: Hôpital général de Douala, Cameroun, Université de Yaoundé I, Faculté de médecine et des sciences biomédicales, Cameroun.
authors.forename: Priso Eugène
authors.initials: PE
authors.lastname: Belley
mesh_terms: D000017:ABO Blood-Group System / Q000097:blood; D001034:Apgar Score; D005260:Female; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D008423:Maternal Age; D011247:Pregnancy / Q000097:blood*; D011262:Pregnancy Trimester, Second / Q000097:blood; D011263:Pregnancy Trimester, Third / Q000097:blood; D014841:von Willebrand Factor / Q000032:analysis*
chemical_list: D000017:ABO Blood-Group System; D014841:von Willebrand Factor
keywords: level; pregnancy; vWF